US government threatens Novo Nordisk with fine for discount program violations

The Danish pharmaceutical company, among others, is in non-compliance with US law and thus risks penalty, say US health authorities.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk and five other pharmaceutical companies have sued the US government – they argue the US discount system is poorly implemented in several US hospitals, driving uppatient costs.

The US Health Resources and Services Administration (HRSA) now responds by threatening a fine of USD 5,000 (DKK 31,741) per violation of the discount program in question, Danish business daily Børsen reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs